# A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

> **NCT06350279** · PHASE1 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HSK39297

## Key facts

- **NCT ID:** NCT06350279
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-25
- **Primary completion:** 2024-08-02
- **Final completion:** 2024-09-29
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350279, "A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06350279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*